<DOC>
	<DOCNO>NCT00236587</DOCNO>
	<brief_summary>The purpose study document long term safety long-acting injectable formulation risperidone treatment patient schizophrenia previously treat long-acting risperidone . Efficacy also evaluate .</brief_summary>
	<brief_title>A Long Term Study Long-acting Injectable Risperidone Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>This open-label , long-term study flexible dose long-acting injectable formulation risperidone ( risperidone LAI ) inject muscle 2 week interval least 12 month patient diagnose schizophrenia . It extension open label study patient schizophrenia ( RIS-USA-259 ) switch treatment oral antipsychotic medication long-acting injectable risperidone . Safety evaluation include incidence adverse event , physical examination , clinical laboratory test ( biochemistry , hematology , urinalysis ) , electrocardiogram ( ECGs ) , Extrapyramidal Symptom Rating Scale ( ESRS ) , scale assess muscle tone , gait , abnormal movement . Efficacy assessment include measurement use Positive Negative Syndrome Scale Schizophrenia ( PANSS ) Clinical Global Impression-Severity Illness scale ( CGI-S ) . Risperidone ( 25-50milligrams [ mg ] ) injection , long-acting formulation , every 2 week least 1 year . Dosages may increase ( 50 mgs maximum ) decrease discretion investigator . Supplementary risperidone tablet ( 1mg ) may administer .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Completion RISUSA256 within 7 day History neuroleptic malignant syndrome , rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness Significant untreated unstable medical illness diabetes , hypertension , angina Serious illness liver , kidney , significant disturbance cardiac , pulmonary , gastrointestinal , endocrine , neurological system Pregnant nursing female , lack adequate contraception Known hypersensitivity unresponsiveness risperidone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Intramuscular injection</keyword>
	<keyword>Antipsychotic agent</keyword>
	<keyword>Long-acting risperidone</keyword>
</DOC>